An innovation in glaucoma surgery: XEN45 gel stent implantation

Arq Bras Oftalmol. Nov-Dec 2017;80(6):382-385. doi: 10.5935/0004-2749.20170093.


Purpose: To report follow-up data for patients who underwent XEN45 gel stent implantation, a new method of minimally invasive glaucoma surgery.

Methods: Fifteen eyes in fifteen patients who underwent XEN45 gel stent implantation surgery were investigated in the study. All patients were examined preoperatively and at the following postoperative time points: 1 day; 1 and 2 weeks; and 1, 2, 3, 6, and 12 months. Intraocular pressure (IOP) was measured via Goldmann applanation tonometry. Combined surgical procedures (XEN45 + phacoemulsification + intraocular lens) were performed in patients who that had cataracts in addition to glaucoma.

Results: The mean IOP values were significantly lower than the preoperative values at all postoperative visits (p<0.001). In two patients, the IOP exceeded 20 mmHg 12 months after surgery. These IOP increases were controlled by medical therapy, and none of the patients needed another surgical procedure.

Conclusion: XEN45 gel stent implantation is a minimally invasive glaucoma surgery that ensures the effective reduction of IOP. This new treatment modality also avoids the destructive complications encountered in other invasive surgical procedures. However, further studies with greater numbers of patients and longer follow-up periods are needed to clarify certain points.

Trial registration: NCT02006693 NCT02036541.

MeSH terms

  • Aged
  • Female
  • Glaucoma / surgery*
  • Humans
  • Male
  • Middle Aged
  • Minimally Invasive Surgical Procedures
  • Prosthesis Design
  • Prosthesis Implantation / methods*
  • Retrospective Studies
  • Stents*
  • Treatment Outcome
  • Visual Acuity

Associated data